Trial Profile
A Phase I/II Safety Study of Planned BPX-501 T Cell Infusion After Partially Mismatched, Related, HSCT in Adults With Advanced Hematologic Malignances at High Risk for Relapse
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Bellicum Pharmaceuticals
- 24 Oct 2019 Planned End Date changed from 1 Dec 2021 to 1 May 2019.
- 30 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.